Saturday, October 17, 2026 from 1:45 p.m. to 3:15 p.m. MDT at Salt Palace Convention Center - Ballroom E
This session is being recorded.
Learn MoreAvailable for 1.50 hours of CPE creditActivity Number: 0204-9999-26-346-L01Activity Type: An Application-Based ActivityThe purpose of this session is to review drugs that have been assigned a Risk Evaluation and Mitigation Strategy (REMS) from the FDA and are commonly used in pediatrics. We will review the history of the FDA’s REMS program and discuss specifics about some of the individual drugs, including adverse effects, reasons for the REMS designation, monitoring parameters, counseling points, and details of the REMS requirements. We will review the requirements for the REMS documentation programs as well as audits and how pharmacies can prepare for a successful audit.
This activity is approved for Board Certified Pediatric Pharmacy Specialist (BCPPS) recertification credit.
The BCPPS Clinical Sessions are part of the professional development program for the recertification of board-certified Pediatric pharmacists by the Board of Pharmacy Specialties and jointly provided by ACCP and the American Society of Health-System Pharmacists (ASHP). In order to earn the BCPPS recertification credit, participants must attend the session, claim continuing pharmacy education credit, and pass the associated posttest(s). Access to the Clinical Session posttests will be available on December 16, 2026, at www.accp.com/myaccount to anyone who has purchased access to the BCPPS posttests. For participants who have not purchased access to the posttests, access can be purchased until 12:00 p.m. on Tuesday, October 20th, at the ACCP Registration Desk. The deadline to submit posttests for these sessions will be December 14, 2027.
Learning Objectives1. Describe the history and purpose of the Food and Drug Administration (FDA)’s risk evaluation and mitigation strategies (REMS) programs.
2. List the adverse effects and monitoring parameters for common REMS medications utilized by children.
3. Describe mitigation and prevention strategies for common REMS medications utilized by children.
4. List documentation requirements for REMS drugs, including vigabatrin, ravulizumab/eculizumab, fenfluramine, bosentan, and isotretinoin.
5. Evaluate your pharmacy’s policies and procedures for handling REMS medications and assess for compliance with REMS audit requirements.
 | | Speaker: | Rachel S. Meyers, Pharm.D., BCPPS, BCPS | | Ernest Mario School of Pharmacy, Rutgers University
Cooperman Barnabas Medical Center | | View Biography |
|
 | | Speaker: | Emily A. Sheskey, Pharm.D., BCPPS |
|
 | | Speaker: | Marla C. Tanski, Pharm.D., MPH, MS, BCPPS | | Clinical Pharmacy Manager
Residency Program Director, PGY2 Pediatrics
Johns Hopkins All Children's Hospital
|
|